BLINCYTO® (blinatumomab)
blincyto.com
Actively hiring
Vaccines
Hospitals & Health Systems
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
Omega Funds
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Omega Funds Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable…
GIVAX is developing a new class of vaccines to protect children from severe gastroenteritis caused by rotavirus and norovirus. Leveraging…
Medical letter drafts, referrals and admissions, payer enquiries and digital patient questionnaires. aiomics supports rehabilitation and…
Praeferre makes compliance a system, not a scramble. Learn how we work, what to expect, and why organisations trust us with the assurance…
BREYANZI® (lisocabtagene maraleucel) is a CD19-directed, genetically modified, autologous T-cell immunotherapy for adult patients with…
The next great hospitalwon't have a building.. We make ongoing treatment automatic.Starting with GLP-1.
Overview
Learn about BLINCYTO® (blinatumomab), a treatment for adults and children with CD-19 positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL), including how it works and what to expect.
News
BLINCYTO (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR)
Read more
Report
BLINCYTO (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
--Amgen today announced new data demonstrating that adding BLINCYTO to chemotherapy significantly improves disease-free survival in newly diagnosed pediatric patients with National Cancer Institute standard risk B-cell acute lymphoblastic leukemia of aver
Read more
Report